Assertio Therapeutics Stock Performance
| ASRT Stock | USD 0.98 0.03 2.97% |
The firm shows a Beta (market volatility) of 0.82, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Assertio Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Assertio Therapeutics is expected to be smaller as well. At this point, Assertio Therapeutics has a negative expected return of -0.18%. Please make sure to confirm Assertio Therapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Assertio Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Assertio Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
Last Split Factor 1:4 | Last Split Date 2021-05-18 |
1 | Acquisition by Vacirca Jeff L of 34767 shares of Assertio Therapeutics subject to Rule 16b-3 | 09/06/2024 |
2 | Disposition of 38017 shares by Sam Schlessinger of Assertio Therapeutics subject to Rule 16b-3 | 09/16/2024 |
3 | Disposition of 22000 shares by Mckee William of Assertio Therapeutics at 3.1384 subject to Rule 16b-3 | 09/24/2024 |
4 | Acquisition by Sam Schlessinger of 283500 shares of Assertio Therapeutics at 0.79 subject to Rule 16b-3 | 09/30/2024 |
5 | Disposition of 19404 shares by Sam Schlessinger of Assertio Therapeutics subject to Rule 16b-3 | 10/01/2024 |
6 | Assertio Holdings Inc Q2 2024 Earnings Call Highlights Navigating Sales Challenges and ... | 10/09/2024 |
7 | ASRT - Assertio Holdings, Inc. Latest Stock News Market Updates - StockTitan | 10/30/2024 |
8 | Insider Trading | 11/07/2024 |
9 | Assertio Holdings Inc Q3 2024 Everything You Need to Know Ahead of Earnings | 11/08/2024 |
10 | Assertio Reports Third Quarter 2024 Financial Results | 11/11/2024 |
11 | Assertio Holdings, Inc. Q3 2024 Earnings Call Transcript | 11/12/2024 |
12 | Acquisition by Ogrady Brendan P. of 11706 shares of Assertio Therapeutics at 0.85 subject to Rule 16b-3 | 11/14/2024 |
13 | Little Excitement Around Assertio Holdings, Inc.s Revenues As Shares Take 25 percent Pounding | 11/15/2024 |
14 | Acquisition by Heather Mason of 75000 shares of Assertio Therapeutics at 0.8 subject to Rule 16b-3 | 11/18/2024 |
15 | Assertio Holdings, Inc. Director Heather L. Mason Buys 75,000 Shares | 11/21/2024 |
| Begin Period Cash Flow | 64.9 M |
Assertio |
Assertio Therapeutics Relative Risk vs. Return Landscape
If you would invest 118.00 in Assertio Therapeutics on August 30, 2024 and sell it today you would lose (20.00) from holding Assertio Therapeutics or give up 16.95% of portfolio value over 90 days. Assertio Therapeutics is currently does not generate positive expected returns and assumes 4.6364% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Assertio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Assertio Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Assertio Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Assertio Therapeutics, and traders can use it to determine the average amount a Assertio Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0397
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | ASRT |
Estimated Market Risk
| 4.64 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Assertio Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Assertio Therapeutics by adding Assertio Therapeutics to a well-diversified portfolio.
Assertio Therapeutics Fundamentals Growth
Assertio Stock prices reflect investors' perceptions of the future prospects and financial health of Assertio Therapeutics, and Assertio Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Assertio Stock performance.
| Return On Equity | -0.42 | ||||
| Return On Asset | -0.0144 | ||||
| Profit Margin | (0.54) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 44.46 M | ||||
| Shares Outstanding | 95.34 M | ||||
| Price To Earning | 4.93 X | ||||
| Price To Book | 0.72 X | ||||
| Price To Sales | 0.74 X | ||||
| Revenue | 152.07 M | ||||
| Gross Profit | 138.29 M | ||||
| EBITDA | (222.45 M) | ||||
| Net Income | (331.94 M) | ||||
| Cash And Equivalents | 52.26 M | ||||
| Cash Per Share | 1.09 X | ||||
| Total Debt | 40.91 M | ||||
| Debt To Equity | 0.49 % | ||||
| Current Ratio | 1.00 X | ||||
| Book Value Per Share | 1.38 X | ||||
| Cash Flow From Operations | 49.6 M | ||||
| Earnings Per Share | (4.94) X | ||||
| Market Capitalization | 81.8 M | ||||
| Total Asset | 286.42 M | ||||
| Retained Earnings | (651.54 M) | ||||
| Working Capital | 77.62 M | ||||
| Current Asset | 5.15 M | ||||
| Current Liabilities | 492.4 K | ||||
About Assertio Therapeutics Performance
Assessing Assertio Therapeutics' fundamental ratios provides investors with valuable insights into Assertio Therapeutics' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Assertio Therapeutics is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 509.08 | 315.88 | |
| Return On Tangible Assets | (1.90) | (1.80) | |
| Return On Capital Employed | (1.26) | (1.20) | |
| Return On Assets | (1.16) | (1.10) | |
| Return On Equity | (2.41) | (2.29) |
Things to note about Assertio Therapeutics performance evaluation
Checking the ongoing alerts about Assertio Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Assertio Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Assertio Therapeutics generated a negative expected return over the last 90 days | |
| Assertio Therapeutics has some characteristics of a very speculative penny stock | |
| Assertio Therapeutics has high historical volatility and very poor performance | |
| Assertio Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 152.07 M. Net Loss for the year was (331.94 M) with profit before overhead, payroll, taxes, and interest of 138.29 M. | |
| Latest headline from thelincolnianonline.com: Assertio Holdings, Inc. Director Heather L. Mason Buys 75,000 Shares |
- Analyzing Assertio Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Assertio Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Assertio Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Assertio Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Assertio Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Assertio Therapeutics' stock. These opinions can provide insight into Assertio Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Assertio Stock Analysis
When running Assertio Therapeutics' price analysis, check to measure Assertio Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Assertio Therapeutics is operating at the current time. Most of Assertio Therapeutics' value examination focuses on studying past and present price action to predict the probability of Assertio Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Assertio Therapeutics' price. Additionally, you may evaluate how the addition of Assertio Therapeutics to your portfolios can decrease your overall portfolio volatility.